Delcath Systems to Present Innovative Liver Cancer Treatments at Upcoming Investor Conferences

Delcath Systems to Showcase Innovative Liver Cancer Treatments at Upcoming Conferences

Delcath Systems, Inc., an interventional oncology firm focused on innovative therapies for liver cancers, prepares to present its advancements at two notable investor conferences. Scheduled for November 13, 2024, the Stephens Biotechnology Virtual Fireside Chats will feature Delcath's leadership discussing the company's proprietary products and their potential to improve treatment outcomes for liver cancer patients. Following this, the company will participate in the 15th Annual Craig-Hallum Alpha Select Conference on November 19, 2024, in New York, NY, where executives plan to engage in one-on-one meetings with potential investors and stakeholders. This participation underscores Delcath’s commitment to enhancing visibility in the oncology market while exploring opportunities for collaboration and investment in their innovative therapies.

Delcath’s flagship products, the HEPZATO KIT™ and the CHEMOSAT® Hepatic Delivery System, represent a significant advancement in the treatment of primary and metastatic liver cancers. The HEPZATO KIT combines melphalan, a chemotherapeutic agent, with Delcath's proprietary Hepatic Delivery System (HDS). This FDA-approved system targets metastatic uveal melanoma with unresectable hepatic metastases, allowing for high-dose chemotherapy to be delivered directly to the liver while minimizing systemic exposure. By focusing treatment on the liver, Delcath aims to enhance local tumor response and reduce the adverse effects typically associated with chemotherapy.

In Europe, the CHEMOSAT system is classified as a Class III medical device and has been authorized for use across numerous medical centers. This system allows for localized treatment, which can result in meaningful tumor responses while mitigating hepatotoxicity. Delcath emphasizes that healthcare providers must understand the full prescribing information and associated boxed warnings for the HEPZATO KIT, ensuring safe and effective use. As Delcath prepares for these conferences, it aims to highlight not only its innovative oncology solutions but also its dedication to improving patient outcomes in the liver cancer treatment landscape.

As Delcath Systems moves forward with its conference engagements, the company continues to solidify its position within the interventional oncology sector. By showcasing its specialized products and treatment methodologies, Delcath seeks to foster relationships that could enhance its research and development efforts, ultimately benefiting patients battling liver cancer. The focus on direct delivery systems encapsulates a broader trend in oncology towards personalized and targeted treatment approaches.